Thymidylate Synthase and Dihydropyrimidine Dehydrogenase are Related to Histological Effects of 5-Fluorouracil and Cisplatin Neoadjuvant Chemotherapy for Primary Gastric Cancer Patients

REFERENCES

• Fuchs C. S., Mayer R. J. Gastric carcinoma. N. Engl. J. Med 1995; 333(1)32–41, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hundahl S. A., Phillips J. L., Menck H. R. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy, fifth edition. American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 2000; 88(4)921–932, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kiyabu M., Leichman L., Chandrasoma P. Effects of preoperative chemotherapy on gastric adenocarcinomas. A morphologic study of 25 cases. Cancer 1992; 70(9)2239–2245, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Leichman L., Silberman H., Leichman C. G., Spears C. P., Ray M., et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J. Clin. Oncol. 1992; 10(12)1933–1942, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Takiguchi N., Nunomura M., Koda K., Oda K., Suzuki H., et al. Neoadjuvant chemotherapy with CDDP and 5-fluorouracil for gastric cancer with serosal invasion. Oncol. Rep. 2003; 10(2)433–438, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pinedo H. M., Peters G. F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 1988; 6(10)1653–1664, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Salonga D., Danenberg K. D., Johnson M., Metzger R., Groshen S., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer. Res. 2000; 6(4)1322–1327, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ichikawa W., Uetake H., Shirota Y., Yamada H., Nishi N., et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin. Cancer. Res. 2003; 9(2)786–791, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Terashima M., Fujiwara H., Takagane A., Abe K., Araya M., et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur. J. Cancer. 2002; 38(18)2375–2381, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Leichman C. G., Lenz H. J., Leichman L., Danenberg K., Baranda J., et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 1997; 15(10)3223–3229, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Johnston P. G., Lenz H. J., Leichman C. G., Danenberg K. D., Allegra C. J., et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer. Res. 1995; 55(7)1407–1412, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Leichman L., Lenz H. J., Leichman C. G., Groshen S., Danenberg K., et al. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur. J. Cancer. 1995; 31A(7–8)1306–1310, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246(4935)1306–1309, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Connolly D. T., Heuvelman D. M., Nelson R., Olander J. V., Eppley B. L., et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 1989; 84(5)1470–1478, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Maeda K., Chung Y. S., Ogawa Y., Takatsuka S., Kang S. M., et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996; 77(5)858–863, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Takiuchi H., Hirata I., Kawabe S., Egashira Y., Katsu K. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol. Rep. 2000; 7(4)841–846, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lenz H. J., Leichman C. G., Danenberg K. D., Danenberg P. V., Groshen S., et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol. 1996; 14(1)176–182, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Metzger R., Leichman C. G., Danenberg K. D., Danenberg P. V., Lenz H. J., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 1998; 16(1)309–316, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Takabayashi A., Iwata S., Kawai Y., Kanai M., Taki Y. Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. Int. J. Oncol. 2000; 17(5)889–895, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Satomi D., Takiguchi N., Koda K., Oda K., Suzuki H., et al. Apoptosis and apoptosis-associated gene products related to the response to neoadjuvant chemotherapy for gastric cancer. Int. J. Oncol. 2002; 20(6)1167–1171, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• The General Rules for Gastric Cancer Study. Kanehara and Co Ltd., Tokyo, Japan 1998
   Google Scholar
• Japanese Classification of Gastric Carcinoma. Kanehara and Co Ltd., TokyoJapan 1995
   Google Scholar
• Kuniyasu T., Nakamura T., Tabuchi Y., Kuroda Y. Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 1998; 83(7)1300–1306, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Tahara M., Ochiai A., Fujimoto J., Boku N., Yasui W., et al. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol. Rep. 2004; 11(1)9–15, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nakajima T., Ota K., Ishihara S., Oyama S., Nishi M., et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann. Surg. Oncol. 1997; 4(3)203–208, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Preusser P., Wilke H., Achterrath W., Fink U., Lenaz L., et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J. Clin. Oncol. 1989; 7(9)1310–1317, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Plukker J. T., Mulder N. H., Sleijfer D. T., Grond J., Verschueren R. C. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br. J. Surg. 1991; 78(8)955–958, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wilke H., Preusser P., Fink U., Gunzer U., Meyer H. J., et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J. Clin. Oncol. 1989; 7(9)1318–1326, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lerner A., Gonin R., Steele G. D., Jr., Mayer R. J. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J. Clin. Oncol. 1992; 10(4)536–540, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kelsen D., Atiq O. T., Saltz L., Niedzwiecki D., Ginn D., Chapman D., Heelan R., Lightdale C., Vinciguerra V., Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J. Clin. Oncol. 1992; 10(4)541–548, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Murad A. M., Santiago F. F., Petroianu A., Rocha P. R., Rodrigues M. A., Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72(1)37–41, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ajani J. A., Roth J. A., Ryan B., McMurtrey M., Rich T. A., et al. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J. Clin. Oncol. 1990; 8(7)1231–1238, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chung Y. S., Yamashita Y., Inoue T., Matsuoka T., Nakata B., et al. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 1997; 80(1)1–7, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kondo K., Murase M., Kodera Y., Akiyama S., Ito K., et al. Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology. 1996; 53(1)64–67, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Macdonald J. S. Oral fluoropyrimidines: a closer look at their toxicities. Am. J. Clin. Oncol. 1999; 22(5)475–480, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ninomiya Y., Yanagisawa A., Kato Y., Kitagawa T., Ishihara S., et al. Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. J. Cancer. Res. Clin. Oncol. 1999; 125(12)699–706, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yonemura Y., Kinoshita K., Fujimura T., Fushida S., Sawa T., et al. Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology 1996; 43(11)1260–1272, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nozawa H., Tsukui H., Nishida K., Yakumaru K., Nagawa H., et al. Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma. Cancer Chemother Pharmacol 2002; 49(4)267–273, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Berger S. H., Jenh C. H., Johnson L. F., Berger F. G. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol. Pharmacol. 1985; 28(5)461–467, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kirihara Y., Yamamoto W., Toge T., Nishiyama M. Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int. J. Oncol. 1999; 14(3)551–556, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Washtien W. L. Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil. Mol. Pharmacol. 1984; 25(1)171–177, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Uchida K., Hayashi K., Kuramochi H., Takasaki K. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. Int. J. Oncol. 2001; 19(2)341–346, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schneider S., Uchida K., Brabender J., Baldus S. E., Yochim J., et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J. Am. Coll. Surg. 2005; 200(3)336–344, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ichikawa W., Uetake H., Shirota Y., Yamada H., Takahashi T., et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br. J. Cancer. 2003; 89(8)1486–1492, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar